- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.
This educational activity is designed to provide our faculty with alternative sources of information and experience on controversial areas in diagnostic pathology that cannot be gleaned from reading the literature or standard textbooks in pathology. There are many areas in pathology where a uniformly acceptable standard has not yet been established. Direct interaction with an expert can provide the pathologist with additional insight into more effective ways to handle the issue.
ACCME Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
AMA Credit Designation:
The Medical College of Wisconsin designates this Live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
At the conclusion of this activity, learners will be able to:
- Discuss key disease processes in congenital myopathy, with a specific focus on X-linked myotubular myopathy and nemaline myopathy.
- Discuss the process of treatment development in rare muscle disases, using the development and translation of gene therapy for X-linked myotubular myopathy as an example of the process.
- Discuss the challenges of treatment development in genetically and clinically heterogenous disorders including nemaline myopathy, and the role of biomarker assessment in defining a path forward.
All persons in control of content have NO relevant financial relationships to disclose with the exception of the following and in accordance with the ACCME® standards for Commercial Support Number 6, these relationships were reviewed via the MCW conflict of interest resolution process and resolved.
|Michael W. Lawlor, MD, PhD||Audentes Therapeutics||Board Member, Collaborator|
|Michael W. Lawlor, MD, PhD||Solid Biosciences||Board Member, Collaborator|
|Michael W. Lawlor, MD, PhD||Ichorion Therapeutics||Board Member, Collaborator|
|Michael W. Lawlor, MD, PhD||Wave Life Sciences||Consultant|
|Michael W. Lawlor, MD, PhD||Dynacure||Consultant|